Reticular Subretinal Drusenoid Deposits

Reticular Subretinal Drusenoid Deposits are tiny, spot-like or net-like buildups of material that sit above the retinal pigment epithelium (RPE) in the subretinal space, right under the light-sensing cells of the eye. Doctors often call them reticular pseudodrusen (RPD) or simply subretinal drusenoid deposits (SDD). They are a special pattern of deposits seen in people with age-related macular degeneration (AMD). Unlike “classic” soft drusen that live under the RPE, these deposits live on top of the RPE, closer to the photoreceptors. This location matters because it can affect rod and cone function, especially rod (night-vision) function. AAO JournalPubMedPubMed Central

Subretinal drusenoid deposits (SDD) — also called reticular pseudodrusen — are tiny, pale, mound-like buildups of fatty, cholesterol-like and protein material that collect above the retinal pigment epithelium (RPE) and just beneath the light-sensing photoreceptors in the outer retina. They are different from “classic” drusen (which sit under the RPE). SDD are easiest to see with modern retinal imaging (especially OCT, near-infrared reflectance, and fundus autofluorescence). Finding SDD matters because their presence signals higher risk of worsening age-related macular degeneration (AMD) over time. In simple terms: SDD are surface-like “grit” on top of the support layer for the rods and cones; they stress the night-vision system first and mark eyes that deserve closer follow-up. PubMedPubMed Central+1

SDD/RPD are important because their presence raises the risk of progressing to late AMD, especially geographic atrophy (GA), and sometimes to certain forms of neovascular (“wet”) AMD. They are a recognized third anatomic risk marker for AMD progression, alongside large soft drusen and pigment changes. AAO JournalPubMed+1

People with SDD/RPD often notice worse vision in dim light, slow dark adaptation after lights go off, and reduced contrast sensitivity, even when standard letter acuity looks fairly good. These functional problems track with the presence of RPD and with thinner choroids under the macula. PubMedPubMed Central

On imaging, doctors see SDD/RPD best with multimodal imaging: spectral-domain OCT shows little mounds or cones of reflective material above the RPE, near-infrared reflectance shows dark dots in a net-like pattern, and fundus autofluorescence shows a reticular mosaic of altered signals. Color photos alone often miss them. PubMed Central+1Lippincott Journals

---

Types

1) By OCT stage (structural stages on cross-section)

• Stage 1: tiny, granular hyper-reflective material between the RPE and the ellipsoid zone (no break in the ellipsoid zone).

• Stage 2: the material forms a small mound that deforms the overlying ellipsoid zone.

• Stage 3: a conical deposit that pokes up into the outer retina, crossing the ellipsoid zone.
  These stages describe how the deposit grows “upward” toward the photoreceptors. EyeWikien.octclub.org

2) By morphology / pattern (how they look in images)

• Dot type: scattered small dots.

• Ribbon type: interconnected bands forming a reticular (net-like) pattern.

• Mid-peripheral type: deposits seen further from the fovea.
  These patterns can co-exist and may change over time. AjoScienceDirect

3) By topography

RPD are common superotemporal to the fovea and may spread in a network. They are often hyporeflective on near-infrared, show a reticular pattern on fundus autofluorescence, and appear as hyper-reflective subretinal material on OCT. EyeWiki

Causes

No single cause explains SDD/RPD. Think of the list below as contributors and risk associations that make SDD more likely in an AMD-prone eye.

1. Older age – risk rises with age; RPD are much more common in older adults with AMD. Ajo

2. Female sex – several cohorts show higher odds in women. Ajo

3. AMD genetic background – AMD risk loci (e.g., ARMS2/HTRA1, CFH) relate to RPD load in genetic studies, though findings vary by cohort and phenotype definition. AjoMedRxivAAO Journal

4. Choroidal thinning – eyes with RPD often have a thin choroid, suggesting choroidal perfusion/oxygen issues. PubMed Central+1

5. Outer retina / RPE stress – RPD sit above the RPE and are linked to outer retinal/RPE dysfunction on imaging–histology correlates. AAO Journal

6. Rod vulnerability – RPD relate closely to rod structure/function; patients show impaired dark adaptation beyond what drusen alone explain. PubMed Central

7. Oxidative stress / lipid handling – SDD share some proteins with drusen but differ in lipids, implying altered lipid and oxidative pathways in the subretinal space. PubMed

8. Smoking (general AMD risk) – smoking raises AMD risk and is associated with RPD in population analyses. IOVS

9. High BMI / metabolic factors (general AMD risks) – metabolic stress is associated with AMD and with RPD in epidemiology. IOVS

10. Hypertension / vascular factors – several studies suggest links between RPD and vascular disease or blood-pressure history; others are neutral—evidence is mixed. PubMed CentralBMJ OpenAAO Journal

11. Coronary artery disease (investigated) – some reports note associations; others (e.g., AREDS2 analyses) do not support a strong link. BMJ OpenAAO Journal

12. Systemic cardiovascular risk overall (investigated) – ongoing work explores whether RPD mark systemic vascular risk; current results are inconclusive. IOVSScienceDirect

13. Sleep-disordered breathing / nocturnal hypoxia (hypothesis under study) – small observational signals suggest a possible link between sleep apnea and RPD/AMD; stronger studies are needed. Medical Dialogues

14. Low choroidal perfusion – functional imaging and thickness data point toward vascular insufficiency beneath the RPE as a contributor. PubMed Central

15. Photoreceptor mitochondrial/metabolic stress – outer retinal stress near rods may drive deposit formation and dysfunction (supported by structure-function studies). PubMed Central

16. Inflammation / complement activity (general AMD biology) – complement pathways are central in AMD and likely influence SDD as part of the spectrum. PubMed Central

17. Light/blue-light visibility (phenotypic clue, not a cause) – RPD are more visible in blue-light channels; this is not a cause but reflects their optical properties and location. EyeWiki

18. Intermediate AMD stage – RPD are more prevalent in intermediate AMD and can predict faster progression to late AMD. PubMed Central

19. Type 3 (retinal angiomatous) neovascularization tendency – eyes with RPD show a higher tendency toward type 3 MNV when neovascularization occurs. Nature

20. Natural history dynamics – RPD can appear, merge, or regress, reflecting an active disease process rather than static debris. PubMed Central

---

Symptoms

Many people have no symptoms early on. When symptoms appear, they often involve low-light vision.

1. Poor night vision (nyctalopia): it is hard to see in the dark, and it takes longer to “get used to” darkness. PubMed Central

2. Slow dark adaptation: after turning lights off, vision recovers very slowly compared with peers. PubMed

3. Problems in dim restaurants or at dusk: reading menus or recognizing faces is harder when lighting is low. PubMed Central

4. Reduced contrast sensitivity: gray-on-gray details and low-contrast print are hard to see. PubMed

5. Glare sensitivity: bright headlights or reflections feel harsh after being in the dark. PubMed Central

6. Fluctuating clarity: vision can look okay in bright light but worse in dim light. PubMed Central

7. Subtle central blur: some people notice a soft blur near the center when reading fine print. PubMed Central

8. Words “wash out”: faint letters disappear on gray or colored paper. PubMed

9. Fading of small details: thin lines and textures (e.g., fabric weaves) are less distinct. PubMed

10. Longer recovery after bright light: stepping outside on a sunny day makes it harder to re-read your phone in the shade. PubMed

11. Trouble navigating in movie theaters: early and late steps are hard to judge in the dark. PubMed Central

12. Paracentral dim spots: a few people sense small dim areas just off the center. IOVS

13. Mild metamorphopsia (rare early): straight lines can look a little wavy if other AMD changes coexist. PubMed Central

14. Reading fatigue: more effort is needed to keep clarity for long reading bouts. PubMed

15. Often: no clear symptom at first: many cases are picked up on imaging before the person notices trouble. Lippincott Journals

---

Diagnostic tests

A) Physical examination (in-clinic observation)

1. Best-corrected visual acuity (BCVA): checks letter chart performance. It can be normal early, because RPD mainly hurt low-light and contrast tasks first. The test sets a baseline to track change. AAO Journal

2. Dilated fundus examination: the eye doctor looks at the macula with bright lenses. RPD can be subtle or even missed on white-light exam alone, so exam findings are paired with imaging. Lippincott Journals

3. Contrast sensitivity charts: these charts reveal problems seeing faint stripes/letters and help explain “I can read the chart but still struggle.” PubMed

4. Low-luminance visual acuity (LLVA): the same letter chart is viewed through a neutral density filter to mimic dim light; people with RPD often do worse here than on standard acuity. AAO Journal

B) Manual / functional chairside tests

5. Amsler grid (at home or in clinic): screens for waviness or new spots that could suggest progression toward neovascular AMD; not specific to RPD but useful for monitoring. Review of Optometry

6. Dark-adaptation threshold testing (AdaptDx or similar): measures how quickly vision recovers after a bright bleach. RPD strongly worsen rod-mediated dark adaptation. PubMed

7. Photostress recovery time: bright light is shined, and recovery is timed. Prolonged recovery supports outer-retinal/RPE stress. PubMed Central

8. Reading speed in low light: a simple, practical measure many clinics use to document functional impact in dim settings. PubMed Central

C) Laboratory & pathological / biologic context tests

(These do not diagnose RPD by themselves; they help understand risk or research biology.)

9. Genetic testing for AMD risk loci (e.g., ARMS2/HTRA1, CFH): may inform overall AMD risk and, in some studies, RPD load; results vary by cohort. AjoMedRxiv

10. Systemic cardiovascular risk profile (lipids, blood pressure history, diabetes markers): vascular health is relevant to AMD; RPD–CVD links are under active study and not fully settled. BMJ OpenAAO Journal

11. Inflammation/complement research markers (study settings): complement biology is central in AMD and likely in SDD; at present, these are research tools rather than routine tests. PubMed Central

12. Histopathology (research/rare): tissue studies confirm deposits lie above the RPE and differ in composition from soft drusen. This is not a clinical test but proves the disease biology. AAO JournalPubMed

D) Electrodiagnostic tests (objective retinal function)

13. Multifocal electroretinography (mfERG): can show delayed implicit times (slower cone pathway responses) in eyes with RPD, even when amplitudes are preserved. Helpful for documenting subtle dysfunction. PubMedIOVS

14. Full-field ERG (ffERG): may be normal or only mildly reduced in AMD; not specific for RPD, but can document global rod–cone function when function loss seems generalized. (Use mainly for research or complex cases.) ScienceDirect

15. Pattern ERG / Visual Evoked Potential (PERG/VEP): adjunctive tests to explore macular/optic pathway function when clinical findings and symptoms do not match; supportive, not diagnostic for RPD. ScienceDirect

E) Imaging tests (core to diagnosis)

16. Spectral-domain OCT (SD-OCT): the gold-standard structural test. Shows small hyper-reflective deposits above the RPE that can mound or form conical profiles as they progress (Stages 1–3). En-face OCT highlights their net-like distribution. PubMed CentralEyeWiki

17. Near-infrared reflectance (NIR): shows dark dots in a reticular (net) pattern, often clearer than color photos. It is very helpful to map their extent. PubMed Central

18. Fundus autofluorescence (FAF): shows a mosaic of hypo- and hyper-autofluorescent spots forming a net-like pattern that corresponds to RPD topography. AAO-HNS

19. Color fundus photography (CFP): may show faint, pale dots or a subtle net pattern, but frequently misses RPD; that is why multimodal imaging is essential. Lippincott Journals

20. OCT-Angiography / Indocyanine green angiography (ICGA): OCT-A helps exclude neovascularization when vision suddenly worsens; ICGA can show hypofluorescent reticular lesions. These tools help stratify risk and watch for conversion to wet AMD. EyeWiki

Non-pharmacological treatments

1. Stop smoking, permanently. Smoking accelerates AMD biology; quitting slows harm.

2. Adopt a Mediterranean-style eating pattern (vegetables, leafy greens, legumes, whole grains, nuts, olive oil, fish; minimal processed meat/sugar). Multiple analyses, including AREDS/AREDS2 work, link this pattern with slower AMD worsening (and slower GA enlargement).

3. Regular aerobic activity (most days) to improve vascular health that feeds the choroid.

4. Blood-pressure control — keeps choroidal perfusion steadier.

5. Cholesterol management (diet ± doctor-guided meds) for lipid balance.

6. Diabetes/metabolic control — even modest A1c improvements help microvasculature.

7. Treat obstructive sleep apnea (evaluation and CPAP if indicated) to reduce nocturnal hypoxia burden. PubMed

8. Room-lighting optimization — brighter, even lighting and task lamps reduce strain.

9. High-contrast reading strategies — bold fonts, matte paper/screens, larger print.

10. Low-vision rehabilitation — training and aids (handheld/stand magnifiers, telescopic devices, electronic magnification) to preserve independence when vision drops.

11. Home monitoring — daily Amsler grid; report any new waviness, blur, or blank spots.

12. Tele-monitoring for conversion to wet AMD — selected intermediate-AMD patients benefit from devices like ForeseeHome to catch CNV earlier and preserve more letters. FDA Access Data

13. UV/blue-light protection outdoors — quality sunglasses + brimmed hat.

14. Anti-glare strategies for night driving (clean windshield, anti-reflective lenses).

15. Weight management — improves BP, lipids, sleep apnea, insulin resistance.

16. Anti-inflammatory life habits — more plants/fish, less ultra-processed foods.

17. Limit alcohol (heavy intake tracks with AMD risk; moderation is wiser).

18. Adequate sleep and daylight exposure — supports retinal metabolism and circadian health.

19. Medication review — coordinate with your doctor to avoid non-essential drugs that worsen BP/lipids/sleep.

20. Scheduled dilated eye exams — to act early if SDD-eyes begin to convert to wet AMD or GA.

---

Drug treatments

There is no pill or eye drop that removes SDD. Medicines treat AMD stages/complications that SDD predict: wet AMD (anti-VEGF injections) and geographic atrophy (complement inhibitors). Doses below are typical label regimens; your retina specialist will tailor them.

1. Ranibizumab 0.5 mg (Lucentis®) — Class: anti-VEGF. Dose/Timing: 0.5 mg intravitreal monthly at first, then as-needed/treat-extend. Purpose: stop and dry neovascular/wet AMD. Mechanism: neutralizes VEGF-A to reduce leakage/new vessels. Key side effects: intraocular inflammation, endophthalmitis (rare), IOP rise. Equivalency vs bevacizumab was shown in CATT.

2. Aflibercept 2 mg (Eylea®) — Class: anti-VEGF/VEGF-trap. Dose/Timing: 2 mg monthly ×3, then every 8 weeks (many extend further). Purpose/Mechanism/Side effects: as above.

3. Aflibercept 8 mg (Eylea® HD) — Class: high-dose anti-VEGF. Dose/Timing: 8 mg monthly ×3, then every 8–16 weeks. Advantage: longer intervals for some patients. Risks: similar class warnings.

4. Faricimab 6 mg (Vabysmo®) — Class: bi-specific (anti-VEGF-A + anti-Ang-2). Dose/Timing: monthly ×4, then extend (often 8–16 weeks when stable). Purpose: durability via dual-pathway blockade. Side effects: class-typical.

5. Bevacizumab 1.25 mg (Avastin® off-label) — Class: anti-VEGF. Dose/Timing: 1.25 mg monthly/treat-extend; equivalent vision outcomes to ranibizumab when dosed the same in trials. Note: compounded; discuss sourcing/safety.

6. Brolucizumab 6 mg (Beovu®) — Class: anti-VEGF. Dose/Timing: q4–6 weeks loading, then q8–12 weeks. Note: effective drying; monitor for intraocular inflammation/vasculitis risks highlighted in label.

7. Ranibizumab Port-Delivery System (Susvimo®) — Class: surgical implant that continuously delivers ranibizumab; Timing: refill every ~24 weeks. Use: for patients who already respond to anti-VEGF but want fewer visits. Risks: device/surgical complications; boxed warning for endophthalmitis.

8. Pegcetacoplan 15 mg (Syfovre®) — Class: complement C3 inhibitor for geographic atrophy (dry AMD late stage). Dose/Timing: intravitreal every 25–60 days (monthly or every-other-month). Purpose: slows GA growth (does not restore lost tissue). Risks: inflammation, rare occlusive vasculitis; discuss pros/cons.

9. Avacincaptad pegol 2 mg (Izervay™) — Class: complement C5 inhibitor for GA. Dose/Timing: 2 mg monthly. Purpose: slows GA enlargement. Risks: class-typical injection risks; discuss ischemic events warnings with your specialist.

10. Verteporfin (Visudyne®) photodynamic therapy — Class: photosensitizer used with laser for certain CNV patterns. Dose/Timing: 6 mg/m² IV over 10 min, then non-thermal red-light activation ~15 min after start of infusion; retreat q3 months if leakage recurs. Use now: niche (e.g., polypoidal/choroidal variants). Risks: photosensitivity precautions for 48 h.

Important: only your retina specialist can decide if/when these are appropriate. Doses can change with new data and your individual response.

---

Dietary “molecular” supplements

The only supplement formula proven to slow AMD progression in appropriate patients is the AREDS2 blend. It does not cure SDD/AMD, but in intermediate AMD it lowers the chance of reaching late AMD. Omega-3 add-ons did not improve outcomes in AREDS2. Beta-carotene was removed due to lung-cancer risk in current/former smokers.

1. Lutein 10 mg/day — pigment carotenoid that concentrates in the macula; supports antioxidant filtering of blue light. (Part of AREDS2.)

2. Zeaxanthin 2 mg/day — companion carotenoid; stabilizes macular pigment. (AREDS2.)

3. Vitamin C 500 mg/day — antioxidant; reduces oxidative stress load. (AREDS2.)

4. Vitamin E 400 IU/day — lipid-phase antioxidant for photoreceptor/RPE membranes. (AREDS2.)

5. Zinc 80 mg/day (as zinc oxide) — supports retinal enzyme function and antioxidant defenses; must pair with copper. (AREDS2.)

6. Copper 2 mg/day (cupric oxide) — prevents copper-deficiency anemia from high-dose zinc. (AREDS2.)

7. Dietary omega-3s from fish (2–3 servings/week) — heart/vascular benefit; supplement pills did not add benefit in AREDS2, so prefer food.

8. Dietary anthocyanins (berries, purple foods) — supportive antioxidants via food patterns; evidence as pills for AMD is limited.

9. Dietary nuts/alpha-linolenic acid (walnuts/flax) — cardiometabolic support within Mediterranean eating.

10. Whole-diet approach — the pattern (Mediterranean) beats any single pill for most people.

Always discuss supplements with your doctor (drug interactions, kidney issues, anticoagulants, smoking history, and zinc dose tolerance).

---

Regenerative / stem-cell” therapies

There is no safe “immunity booster” for SDD/AMD. In fact, AMD often involves over-active complement (part of immunity), so approved drugs dampen complement rather than boost it.

1. Pegcetacoplan (C3 inhibitor) — immuno-modulator that slows GA growth (monthly or every-other-month injections; see above). Dose: 15 mg per injection.

2. Avacincaptad pegol (C5 inhibitor) — monthly immuno-modulator for GA (2 mg).

3. Gene therapy to raise complement factor I (GT005) — investigational AAV therapy aiming to rebalance complement; no approved dose in routine care. FDA Access Data

4. AAV gene therapy for soluble CD59 (HMR59/AAVCAGsCD59) — investigational complement brake; no clinical-care dose. FDA Access Data

5. RPE stem-cell replacement (embryonic/iPSC-derived RPE) — early-phase trials show feasibility/safety signals, but no approved, standardized treatment or dose; beware unregulated clinics. FDA Access DataVeterans Affairs

6. Encapsulated cell therapy (CNTF, NT-501) — neurotrophic support concept; mixed trial results and not routine care. Dose varies by device; investigational. FDA Access Data

If you see “stem-cell cure” ads, be cautious. Stick with academic trials or approved therapies discussed with a retina specialist.

---

Procedures & surgeries

1. Intravitreal injections (anti-VEGF or complement inhibitors) — Procedure: in-office numbed injection; Why: treat wet AMD or slow GA growth in at-risk SDD eyes that progress.

2. Ranibizumab Port-Delivery System (Susvimo®) implantation — Procedure: brief eye surgery to place refillable implant; Why: reduce injection burden in responders.

3. Photodynamic therapy with verteporfin — Procedure: IV drug + targeted non-thermal laser; Why: niche CNV patterns or polypoidal cases. Dose: 6 mg/m² verteporfin before laser activation.

4. Pneumatic displacement + tPA (for large submacular hemorrhage from new wet AMD) — Procedure: gas bubble + clot-softening medicine ± vitrectomy; Why: move blood off the fovea to preserve vision.

5. Pars plana vitrectomy — Procedure: micro-surgery to remove vitreous; Why: address non-clearing hemorrhage, severe traction, or endophthalmitis after injections.

---

Prevention tips

1. Don’t smoke (and avoid second-hand smoke).

2. Eat Mediterranean-style most days.

3. Exercise regularly (walk, cycle, swim).

4. Keep blood pressure, lipids, and sugar well-controlled.

5. Treat sleep apnea if present. PubMed

6. Wear UV-blocking sunglasses and a brimmed hat outdoors.

7. Use bright, even room lighting for near work.

8. Keep a home Amsler grid and check both eyes weekly.

9. Keep your eye appointments; imaging finds changes before you feel them. PubMed

10. Discuss AREDS2 supplements with your doctor if you have intermediate AMD or as advised.

---

When to see a doctor

• Immediately if you notice new distortion (wavy lines), a dark/blank spot, sudden blur, new bleeding, or a gray curtain — these can mean wet AMD or other urgent problems.

• Soon (days to weeks) if night driving worsens quickly, if your Amsler grid looks different, or if vision seems dimmer in one eye.

• Routinely as advised (often every 3–12 months) for dilated exams and imaging in eyes with SDD.

---

What to eat — and what to avoid

Eat more of:

1. Leafy greens (spinach, kale) — rich in lutein/zeaxanthin.

2. Orange/yellow veg (corn, peppers) — carotenoids.

3. Oily fish (salmon, sardine, mackerel) 2–3×/week.

4. Legumes and beans — fiber and antioxidants.

5. Mixed nuts (small handful) — healthy fats.

6. Berries and citrus — vitamin C and polyphenols.

7. Olive oil — main cooking fat.

8. Whole grains — steady energy, vascular health.

9. Eggs (yolks contain lutein/zeaxanthin).

10. Plenty of water — hydration for comfort.

Avoid or cut down:

1. Smoking/nicotine in any form.

2. Processed meats and trans-fat snacks.

3. Sugary drinks and ultra-processed sweets.

4. Excess alcohol (keep light/moderate at most).

5. Frequent deep-fried fast foods.

(These choices align with Mediterranean-style eating and AMD evidence.)

---

Frequently asked questions

1. Do SDD always mean I’ll lose central vision?
   No. SDD are a risk flag, not a sentence. With healthy habits and timely care, many people maintain useful vision for years. PubMed Central

2. Are SDD the same as drusen?
   No. Classic drusen sit under the RPE; SDD sit above it, closer to the photoreceptors. PubMed

3. Why is my night vision worse first?
   Because SDD stress the rod system, which handles dim-light seeing and dark adaptation. PubMed Central

4. Can glasses or cataract surgery fix SDD?
   They can improve clarity if refractive error or cataract is present, but they don’t remove SDD.

5. Is there a drop or pill that dissolves SDD?
   No. Treatment focuses on AMD risk reduction and, if needed, injections for wet AMD or GA.

6. Should I start AREDS2 vitamins?
   Only if your eye doctor confirms you’re in the right AMD stage (often “intermediate”). AREDS2 is not for everyone.

7. Do omega-3 capsules help?
   In AREDS2, omega-3 pills did not add benefit; get omega-3s mainly from fish within a healthy diet.

8. Can diet really slow damage?
   Stronger Mediterranean-diet adherence is associated with slower AMD progression (including slower GA growth).

9. How often are injections needed for wet AMD?
   It varies. After a loading phase, many extend to 8–16 weeks depending on the drug and response. Your retina specialist individualizes the plan.

10. What about complement drugs for dry AMD?
    Pegcetacoplan (monthly or every-other-month) and avacincaptad (monthly) can slow GA growth; they do not restore dead retina.

11. Is photodynamic therapy still used?
    Sometimes, for specific CNV patterns. It uses verteporfin 6 mg/m² plus laser activation.

12. Are stem-cell cures available now?
    No approved stem-cell cure yet; only clinical trials. Avoid commercial “stem-cell clinics.” FDA Access Data

13. Can sleep apnea affect my eyes?
    OSA is linked with vascular stress and has been associated with the reticular pseudodrusen phenotype; treating OSA helps overall risk. PubMed

14. How do doctors spot SDD?
    OCT, near-infrared reflectance, and fundus autofluorescence are the most helpful imaging tests. PubMed

15. What’s the single best thing I can do today?
    If you smoke, quit. Then move toward a Mediterranean-style plate and keep your follow-ups.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 23, 2025.